Media Centre
Latest press releases
-
Gefurulimab demonstrates statistically significant and clinically meaningful improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) at week 26 with clinically meaningful improvement seen as early as week one in adults with gMG in PREVAIL Phase III trial
-
Alexion data presented at 2025 AANEM Annual Meeting and MGFA Scientific Session underscores pioneering C5 inhibition leadership in gMG
-
Koselugo approved in the EU for plexiform neurofibromas in adults with neurofibromatosis type 1
-
Tezspire approved in the EU for chronic rhinosinusitis with nasal polyps
-
Datroway demonstrated an unprecedented median overall survival improvement of five months vs. chemotherapy as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option in TROPION-Breast02
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
